TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01145638
Drug: iron sulphate
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 200 mg per day (100 mg bid),12 weeks
Study: NCT00789074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1mg BD
Study: NCT01490398
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
Study: NCT01407003
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single or multiple doses of LIK066
Study: NCT01407003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single or multiple doses of a matching placebo
Study: NCT04531462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04590742
Drug: melatonin 6mg
Normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of melatonin (6mg) given to patient
Study: NCT00905684
Drug: EE30/DRSP (Yasmin, BAY86-5131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients under regular daily life treatment receiving Yasmin according to local drug information
Study: NCT00905684
Drug: Any other OC
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients under regular daily life treatment receiving any other OC according to local drug information
Study: NCT02740972
Drug: NS-065/NCNP-01
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04437160
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
Study: NCT01172405
Drug: Ibuprofen plus caffeine
Normalized name: caffeine / ergotamine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
Study: NCT01172405
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One or two tablets of ibuprofen 400 mg when presenting headache.
Study: NCT04590742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient given 6 weeks of placebo tablet
Study: NCT04048304
Drug: duration of standard antibiotic therapy
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
Study: NCT02292784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
Study: NCT03603366
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
Study: NCT02815189
Drug: Acetaminophen 325 mg for Flare up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will be evaluated a week after completion the clinical procedures.
Study: NCT03856658
Drug: Heparinized Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
Study: NCT00559494
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
Study: NCT00559494
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 250cc via central line similar to minocycline arm administration protocol
Study: NCT02373371
Drug: Metvix®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01659554
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
Study: NCT00821444
Drug: B16 Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tablet, single dose X 3
Study: NCT01850108
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
Study: NCT01413932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD oral dosing
Study: NCT00870103
Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop every 6 hours into the study eye
Study: NCT04161339
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amido pills/daily for 8 weeks
Study: NCT03699475
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GVHD prophylaxis
Study: NCT00539760
Drug: GSK1827771
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1827771 will be administered using injection via subcutaneous (SC) route.
Study: NCT00539760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to GSK1827771 for Injection will be administered via SC route
Study: NCT03932006
Drug: Fengshigutong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fengshigutong Capsule 1.2g twice a day,orally
Study: NCT00157040
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06177574
Drug: BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
Study: NCT00052351
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00052351
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03616223
Drug: FX-322
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
Study: NCT03616223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic injection
Study: NCT04713527
Drug: Enteral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
Study: NCT01523301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches
Study: NCT01087801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline for Injection
Study: NCT01684306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
Study: NCT02912884
Drug: No cytoreductive vs cytoreductive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
Study: NCT01447628
Drug: Ferinject or CosmoFer
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, 1000 mg iron
Study: NCT03087773
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive Placebo orally once daily for 26 weeks.
Study: NCT02341794
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
Study: NCT04149015
Drug: paclitaxel ,oxaliplatin,fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
Study: NCT04512339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
Study: NCT03558984
Drug: D-PLEX
Normalized name: Kleer Plex
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
Study: NCT00025727
Drug: GW433908
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04592731
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
Study: NCT00895011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose 30 minutes prior to initiation of sexual activity
Study: NCT01430754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, daily
Study: NCT05586711
Drug: vaginal DHEA 6.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
Study: NCT01343823
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as two SC 3 mL injections
Study: NCT00177047
Drug: Cyclophosphamide + Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
Study: NCT00923364
Drug: Cyclophosphamide (CTX, Cytoxan)
Normalized name: cyclophosphamide Oral Tablet [Cytoxan]
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
Study: NCT01011478
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02618824
Drug: Histidine Tryptophan Ketoglutarate Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
Study: NCT01463332
Drug: I.V injection of 10 ml normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
Study: NCT03044639
Drug: Lipid Emulsions, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
Study: NCT01039025
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.
Study: NCT03600623
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
Study: NCT00671359
Drug: TR-701 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-701 600mg
Study: NCT00075270
Drug: GW572016 (Lapatinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GW572016 Lapatinib
Study: NCT01843647
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression.
Study: NCT01568528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
Study: NCT00663611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT00308347
Drug: Placebo / Duration of Treatment: mean 3.4 years
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04399746
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg once daily for 4 days
Study: NCT04164693
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients began to use low molecular weight heparin or warfarin sodium tablets.
Study: NCT02513147
Drug: 2 NRTI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06441526
Drug: anti-tumour necrosis factor α antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological drug
Study: NCT00179166
Drug: TPN nutritional supplement
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
Study: NCT03920722
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
Study: NCT00221052
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00274924
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00274924
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00803530
Drug: ATO + Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution.
Study: NCT00116207
Drug: ORAL ANTIOXIDANT
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of triple antioxidant combination therapy vs placebo.
Study: NCT03412994
Drug: standard second-line chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second line standard chemotherapy regimen recommended by the NCCN
Study: NCT02102022
Drug: ADI-PEG 20 plus modified FOLFOX6
Normalized name: PEG-20 stearate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00179218
Drug: nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
Study: NCT02311543
Drug: TachoSil® patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
Study: NCT03789058
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
Study: NCT00155259
Drug: Docetaxel , Cisplatin , Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02962869
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
Study: NCT00533585
Drug: BAY 43-9006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
Study: NCT01230853
Drug: Placebo Comparator B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Matching Placebo Infusion
Study: NCT01230853
Drug: Active Comparator B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
Study: NCT04676971
Drug: hzVSF-v13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Study: NCT01230853
Drug: Placebo Comparator A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Matching Placebo Infusion
Study: NCT02231788
Drug: Telminuvo®Tab. 40/2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study: NCT00730431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
Study: NCT01609478
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo delivered via Concept 1 inhaler
Study: NCT02737033
Drug: Rhodiola
Normalized name: RHODIOLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea 800mg
Study: NCT02737033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: innocuous pill manufactured to mimic Rhodiola
Study: NCT02426125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03080077
Drug: Ricrolin+
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
Study: NCT03080077
Drug: Epi-Off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
Study: NCT04141670
Drug: S48168
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel oral small molecule which is designed to repair leaky RYR1 channels
Study: NCT02578368
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m², d1, i.v., every 2 weeks
Study: NCT01119352
Drug: AZD7687
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
Study: NCT03706924
Drug: VM-1500FDC
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
Study: NCT03706924
Drug: Elpida®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elpida®, capsules, elsulfavirine 20 mg
Study: NCT03706924
Drug: Truvada®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
Study: NCT00663247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 grams daily for 3 months
Study: NCT01658813
Drug: 5-Fluorouracil and Interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil Interferon-alfa-2b
Study: NCT00938886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched naltrexone placebo